These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26356639)

  • 21. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
    Kristensen LE; Saxne T; Nilsson JA; Geborek P
    Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.
    Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA
    Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
    Pavelka K; Kavanaugh AF; Rubbert-Roth A; Ferraccioli G
    Rheumatology (Oxford); 2012 Jul; 51 Suppl 5():v12-21. PubMed ID: 22718922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanded table: some biologic agents and JAK inhibitors for RA.
    Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
    [No Abstract]   [Full Text] [Related]  

  • 33. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.
    Curtis JR; Schabert VF; Yeaw J; Korn JR; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier D
    J Med Econ; 2014 Aug; 17(8):555-66. PubMed ID: 24754646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
    Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
    Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded Table: Some biologic drugs and JAK inhibitors for rheumatoid arthritis.
    Med Lett Drugs Ther; 2021 Nov; 63(1637):e187-e189. PubMed ID: 35085212
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic.
    Johnston SS; McMorrow D; Farr AM; Juneau P; Ogale S
    Rheumatol Ther; 2015 Jun; 2(1):59-71. PubMed ID: 27747492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
    Jones G; Darian-Smith E; Kwok M; Winzenberg T
    Biologics; 2012; 6():155-61. PubMed ID: 22848148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2021 Nov; 63(1637):177-184. PubMed ID: 35085210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.